Dr. Bellamkonda K. Kishore, M.D., Ph.D., CBiol., FASN
Study:
*MBBS-KMC 1971-75.
*Internship, GGH, Kurnool 1976.
*M.D. (Biochemistry) Banaras Hindu University, Varanasi 1977-80.
*Advanced renal research and training, Niigata Univ. School of Medicine, Japan 1981-83.
*Ph.D. in Cell Biology and Pharmacology, Catholic University of Louvain and the International Institute of Cellular and Molecular Pathology, Brussels, Belgium 1987-90.
Work:
*Tutor & Research Associate, Biochemistry Dept., AIIMS, New Delhi 1980-81.
*Assistant Professor of Biochemistry, Private Medical Colleges in Karnataka, 1985-86.
*Assistant Professor of Cellular Pharmacology, Catholic University of Louvain and International Institute of Cellular and Molecular Pathology, Brussels, Belgium 1991-92.
*Visiting Fellow, Laboratory of Kidney and Electrolyte Metabolism, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland, 1993-97.
*Research Assistant Professor of Medicine, Univ. of Cincinnati Medical Center, Cincinnati, Ohio 1997-2001.
*Associate Professor of Medicine and Physiology, Univ. of Utah Health Sciences Center, and Nephrology Research Investigator, George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah 2001-current Home page.
Current Research Activities:
Dr. Kishore heads a renal research laboratory at the Salt Lake City VA Medical Center funded by the US National Institutes of Health, US Department of Veterans Affairs, and private foundations.
His lab currently focuses on:
*Purinergic regulation of renal water transport in health and disease.
*Pathophysiology of acquired nephrogenic diabetes insipidus.
*Pathophysiology of polyuric acute renal failure.
*Induction of native erythropoietin in the kidney.
Distinctions:
- Chartered Biologist (CBiol), Institute of Biology, London, UK 1988.
- Citation in the European Biographical Directory, Brussels, 1991-92.
- Citation in the Marquis Who’sWho in America, 2002-current.
- Citation in the Marquis Who'sWho in Medicine and Healthcare, 2004-current
- Fellow of the American Society of Nephrology (FASN) 2004-09.
- Recognition by the Ion Channel Media Group
International Patents:
* Composition and Methods Related to Production of Erythropoietin (WIPO/2004/091495).Patent1.
* Methods and Compositions for Treating Nephrogenic Diabetes Insipidus (WIPO/2006/060079).Patent2.
Activities at the National Level:
* Member, Editorial Board, American Journal of Physiology (Renal Physiology) 2002-current.
* Member, Animal Care and Experimentation Committee of the American Physiological Society (2006-08).
*Ad hoc reviewer, regular Study Sections and/or special emphasis panels of the National Institutes of Health, Bethesda, Maryland; US Department of Veterans Affairs, Washington DC; and Wellcome Trust, London, UK.
*Ad hoc Reviewer for all major kidney journals in the USA and Western Europe.
*Chairing Scientific Sessions and Symposia at the National Conferences.
*Expert Consultant: The Council of Healthcare Advisors, The Gerson Lehrman Group, New York, NY and MEDA Corp (Leerink Swann & Company), Boston, MA.
Professional Memberships:
*Institute of Biology, London, UK.
*American Society of Nephrology.
*International Society of Nephrology.
*American Physiological Society.
*American Heart Association (Kidney Council).
*National Kidney Foundation.
*Nephrogenic Diabetes Insipidus Foundation.
Publication Record:
* About 60 peer reivewed research articles, proceedings, book chapters and theses.Peer reviewed publications.
* More than 100 presentations at the national and international conferences.Books on Amazon.com that cited Kishore’s research work .
Community Activities and Service:
*National Associate Member of the Smithsonian Institution, Washington DC.
*Bronze Leader, Disabled American Veterans Commanders Club.
*Research Mentoring of minority undergraduate students and high school students.
*Participation in Diversity Programs at the University and VA Medical Center.
*Supporting local cultural and temple activities.
Favorite Quote:
"Research and research alone holds the key for the cures of intractable human diseases, and for improving the quality of human life."
